ER-100: Has the First Human Trial of Cellular Rejuvenation Begun?
ER-100 may represent one of the most important longevity experiments to reach humans. The experimental gene therapy uses controlled expression of three transcription factors—OCT4, SOX2 and KLF4, collectively known as OSK—to try to restore more youthful patterns of gene activity in damaged retinal nerve cells. Earlier animal research reported regeneration of injured optic nerves and restoration of visual function in aged mice and mouse models of glaucoma. In 2026, ER-100 entered a first-in-human Phase 1 trial involving people with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. This is fundamentally an early safety study, however, and no human evidence yet demonstrates that ER-100 reverses biological aging, rejuvenates other organs or extends lifespan. The remarkable question now being tested is narrower: can an old or damaged human neuron be induced to function more like a younger one?
National Geographic devoted its September 2026 cover story to one of the biggest questions in longevity science: whether aging can eventually be reversed rather than simply slowed. At the center of the story is ER-100, an experimental gene therapy based on work involving molecular biologists David Sinclair and Yuancheng Lu.
ER-100 uses three cellular reprogramming factors—OCT4, SOX2 and KLF4—to try to restore more youthful patterns of gene activity in damaged retinal nerve cells. Earlier mouse research was unusually provocative, showing regeneration of damaged optic nerves and improvement in visual function in aged animals and experimental glaucoma.
The important development is that this work has now moved into humans. ER-100 is being studied in a small Phase 1 trial involving people with serious optic-nerve disease. The immediate purpose is to establish safety, not to prove that human aging has been reversed.
Still, the question being tested is extraordinary enough on its own. If damaged human neurons can regain meaningful function after partial epigenetic reprogramming, it would suggest that some cellular changes associated with aging may be more reversible than medicine has traditionally assumed. Whether that can eventually be extended to muscle, kidney, brain or the entire body remains an open question.
ER-100 and the Very Real Question of Making Old Cells Young Again
Every so often a longevity story comes along that deserves more than the usual eye roll. ER-100 may be one of them.
National Geographic's September cover story asks whether science could be approaching the end of aging. That is a dramatic way to frame a field that has already produced its share of oversized claims, but beneath the headline is a serious experiment that deserves attention.
ER-100 is an experimental gene therapy now being tested in people with severe optic-nerve disease. Its immediate purpose has nothing to do with helping someone live to 150. Researchers are trying to determine whether damaged retinal nerve cells can be pushed toward a more youthful biological state and, more importantly, whether those cells can recover function that has already been lost.
If that turns out to be possible in humans, the implications become considerably more interesting.
Why the Eye?
The eye is an unusually practical place to begin this kind of research. Treatment can be delivered locally, retinal tissue can be examined in extraordinary detail and changes in vision give researchers something meaningful to measure.
ER-100 grew out of work involving molecular biologists David Sinclair and Yuancheng Lu and uses three transcription factors known as OCT4, SOX2 and KLF4, collectively called OSK. These belong to the family of cellular reprogramming factors made famous by Nobel Prize-winning researcher Shinya Yamanaka.
Yamanaka's work demonstrated that mature cells are not necessarily permanently locked into their biological state. Under the right circumstances, their programming can be changed.
That discovery also exposed the problem researchers now have to solve. Push a mature cell too far backward and it can lose the identity that makes it useful. A retinal cell that forgets it is a retinal cell isn't much help to someone with glaucoma, and uncontrolled reprogramming raises legitimate concerns about abnormal cell growth and cancer.
The appeal of partial reprogramming is the possibility that scientists may be able to move a cell toward a more youthful state without erasing what that cell is supposed to be.
The Mouse Research Was Hard to Ignore
The interest surrounding ER-100 did not begin with a magazine cover. Much of it comes from a remarkable 2020 study published in Nature.
Researchers used OSK in retinal ganglion cells, the neurons that carry visual information from the eye toward the brain. In mice, the treatment was associated with younger patterns of DNA methylation and gene expression, regeneration of damaged optic-nerve fibers and improved visual function. Vision also improved in aged mice and in an experimental model of glaucoma.
The most provocative part of that research may not have been the improvement in vision. It was the suggestion that an older cell may retain some memory of its younger biological state.
That raises a fascinating question about aging. Does a cell gradually lose the information that allowed it to function when it was young, or does some of that information remain intact but become increasingly difficult to access?
We don't know the answer yet. But it is a much more interesting scientific question than whether the newest supplement can “turn back your biological clock.”
Read the original Nature study.
ER-100 Has Now Reached Humans
In January 2026, the FDA cleared Life Biosciences' Investigational New Drug application for ER-100, allowing the therapy to enter human testing. That distinction is worth making because FDA clearance to begin a clinical trial is very different from FDA approval of a treatment. ER-100 remains experimental.
The first Phase 1 trial is expected to include up to 18 participants. Twelve are expected to have open-angle glaucoma and six non-arteritic anterior ischemic optic neuropathy, or NAION. Both conditions can damage the retinal ganglion cells and optic nerve.
ClinicalTrials.gov lists the study as beginning March 2, 2026. National Geographic reports witnessing a patient receive ER-100 in April, while Life Biosciences publicly announced its first participant dosing in June.
At this stage, safety is the central issue. Researchers need to know whether partial reprogramming can be attempted in human retinal cells without unacceptable inflammation, immune complications, abnormal cellular behavior or other serious problems. They are also measuring visual function, which means the study may provide early clues about whether the treatment is actually doing anything useful.
View the ER-100 clinical trial.
Does This Mean We Are About to Reverse Human Aging?
No, and saying that does not make ER-100 any less interesting.
There is an enormous biological distance between improving a localized population of retinal neurons and rejuvenating a kidney, a heart, skeletal muscle or the human brain. There is an even greater distance between treating individual tissues and safely altering aging across an entire body.
The eye gives researchers advantages that most organs do not. A therapy can be placed exactly where it is needed and its effects can be followed closely. Whole-body reprogramming would require far greater control over where a treatment goes, which cells receive it, how strongly those cells respond and when the process stops.
Aging is also bigger than the epigenome. Mitochondrial dysfunction, accumulated DNA damage, cellular senescence, chronic inflammation, declining protein quality control, immune changes and the environment surrounding our cells all contribute to the aging process.
Partial epigenetic reprogramming may eventually influence some of those mechanisms. It may turn out to influence several of them at once. Right now, we simply don't know.
What Would Actually Count as a Breakthrough?
The most meaningful result from ER-100 would be fairly straightforward: a patient with damaged retinal neurons regains measurable function because those cells have been successfully reprogrammed.
That would be a major finding without saying anything about immortality or radically extending human lifespan.
Medicine has traditionally approached much of age-related degeneration as a process of preservation. We try to slow the decline, protect what remains and manage the consequences. Regenerative medicine asks a more ambitious question: what if some of that lost function can actually be restored?
If ER-100 eventually demonstrates that an old or injured human neuron can recover meaningful function after partial reprogramming, researchers would have something they have been trying to establish for years: evidence in a living human that at least some aspects of cellular aging or injury may be reversible.
That would be extraordinary enough.
Let the Science Arrive Before the Marketing
Anyone who has followed longevity medicine for very long has seen the familiar pattern. Interesting animal research appears, extraordinary conclusions are drawn from it, and somewhere between the laboratory and social media an experimental finding becomes a treatment, protocol or product.
ER-100 deserves better than that.
There is real biology here, impressive animal research behind it and now a legitimate human clinical trial. There are also enormous unanswered questions, which is exactly where the science is supposed to be at this point.
The more interesting an idea becomes, the more important it is to separate what has actually been demonstrated from what researchers hope might eventually become possible. ER-100 has not shown that human aging can be reversed. It has not yet established that old human retinal cells can be rejuvenated, and it certainly has not demonstrated that partial reprogramming can safely make the rest of the body younger.
What has changed is that the question is finally being tested in humans.
We will be watching closely because the first meaningful result does not need to be dramatic. If scientists can show that a damaged human neuron has recovered function because part of its youthful cellular programming was restored, nobody will need to decorate the finding with promises about living forever.
The result will already be remarkable.
For more of our perspective on evidence, prevention and longevity medicine, visit the HormoneSynergy Longevity Medicine Resource Library or learn more about the HormoneSynergy Optimal Aging Assessment.
Frequently Asked Questions
Is ER-100 FDA approved?
No. The FDA cleared an Investigational New Drug application allowing ER-100 to be studied in humans. That permits clinical testing but does not mean the treatment has been approved. ER-100 remains experimental.
Does ER-100 reverse aging?
That has not been demonstrated in humans. Earlier animal research suggests that OSK reprogramming can restore more youthful epigenetic patterns and improve retinal function, but whether meaningful cellular rejuvenation will occur in people is one of the questions the human research now needs to answer.
What are OSK and the Yamanaka factors?
OSK refers to OCT4, SOX2 and KLF4, three transcription factors involved in cellular reprogramming. They are three of the four factors used in Shinya Yamanaka's Nobel Prize-winning research showing that mature cells can be reprogrammed toward a stem-cell-like state. ER-100 is attempting a more limited form of reprogramming rather than completely resetting a cell's identity.
Why is ER-100 being tested in the eye?
The eye allows a gene therapy to be delivered locally rather than throughout the body. Researchers can also examine retinal structures closely and objectively measure changes in vision, making optic-nerve disease a practical place to begin testing whether partial cellular reprogramming can be performed safely in humans.
Could this eventually rejuvenate the brain, muscles or kidneys?
That is possible in theory but has not been demonstrated in humans. Moving from localized treatment of retinal cells to safe reprogramming of larger organs or the entire body presents major challenges involving delivery, dosing, immune response, cellular identity and long-term safety.
When will we know whether ER-100 works?
The Phase 1 trial currently lists estimated primary completion in May 2027, with longer-term follow-up continuing afterward. Early safety or visual-function findings could potentially be reported sooner, but meaningful conclusions about efficacy will require human clinical data and likely additional trials.
Editorial Transparency
Published August 2026. ER-100 is an investigational therapy undergoing Phase 1 human testing and is not FDA approved for the treatment of glaucoma, aging or any anti-aging indication. HormoneSynergy has no financial relationship with Life Biosciences or ER-100. This article is intended for education and commentary on emerging longevity science. We will continue to follow the research and update our coverage as meaningful human clinical results become available.
Sources
ClinicalTrials.gov — ER-100 Phase 1 Study, NCT07290244
Life Biosciences — First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies
National Geographic — Are We on the Brink of Ending Aging? August 2026.
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →